Abstract
Two cases of stage IV acinar carcinoma of the pancreas are presented. The two patients were treated with several lines of chemotherapies active against colon cancer. At last-line, both patients received panitumumab monotherapy. We describe the tumour response to the different therapies. Our findings demonstrate that panitumumab produces objective responses when used as third-line treatment in the therapy of patients with acinar cell carcinoma of the pancreas. Thus, we propose the consideration of the use of panitumumab in early lines of treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
